Journal
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
Volume 19, Issue -, Pages 4217-4225Publisher
ELSEVIER
DOI: 10.1016/j.csbj.2021.07.023
Keywords
SARS-CoV-2; COVID-19; Coronavirus; Interferon; Immune evasion; Innate immunity
Funding
- National Natural Science Foundation of China [31870162, 82161138003]
- National Key Research and Development Program of China [2018YFA0507202]
- Youth Innovation Promotion Association of Chinese Academy of Sciences
Ask authors/readers for more resources
The ongoing COVID-19 pandemic caused by SARS-CoV-2 has led to unprecedented medical and socioeconomic crises, with viral proteins showing potential antagonistic effects against IFN responses. Understanding the strategies used by SARS-CoV-2 to evade innate immunity, particularly the antiviral IFN responses, will not only help elucidate the infection and pathogenesis, but also aid in the development of antiviral intervention therapies.
The on-going pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to unprecedented medical and socioeconomic crises. Although the viral pathogenesis remains elusive, deficiency of effective antiviral interferon (IFN) responses upon SARS-CoV-2 infection has been recognized as a hallmark of COVID-19 contributing to the disease pathology and progress. Recently, multiple proteins encoded by SARS-CoV-2 have been shown to act as potential IFN antagonists with diverse possible mechanisms. Here, we summarize and discuss the strategies of SARS-CoV-2 for evasion of innate immunity (particularly the antiviral IFN responses), understanding of which will facilitate not only the elucidation of SARS-CoV-2 infection and pathogenesis but also the development of antiviral intervention therapies. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available